Recent advances in developing small-molecule inhibitors against SARS-CoV-2.
Acta Pharm Sin B
; 12(4): 1591-1623, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1293568
ABSTRACT
The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world. Even though several COVID-19 vaccines are currently in distribution worldwide, with others in the pipeline, treatment modalities lag behind. Accordingly, researchers have been working hard to understand the nature of the virus, its mutant strains, and the pathogenesis of the disease in order to uncover possible drug targets and effective therapeutic agents. As the research continues, we now know the genome structure, epidemiological and clinical features, and pathogenic mechanism of SARS-CoV-2. Here, we summarized the potential therapeutic targets involved in the life cycle of the virus. On the basis of these targets, small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Tipo de estudo:
Estudo prognóstico
Tópicos:
Vacinas
Idioma:
Inglês
Revista:
Acta Pharm Sin B
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
J.apsb.2021.06.016
Similares
MEDLINE
...
LILACS
LIS